Market research
SXTC China SXT Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.89
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- VGG2161P1320
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.89
About
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SXTC discussion.
5 years, 4 months ago
China SXT Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 16.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Finally, its free cash flow grew by 77.6% to $-226K since the same quarter in the previous year.
Based on the above factors, China SXT Pharmaceuticals, Inc gets an overall score of 2/5.